Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
暂无分享,去创建一个
C. Di Mario | M. Allinovi | S. Bartolini | F. Perfetto | F. Cappelli | G. Taborchi | S. Morini | E. Vignini | M. di Gioia | M. Gabriele | R. Martone | Sofia Morini | Marco Allinovi
[1] M. Fontana,et al. Cardiac Amyloidosis: Updates in Imaging , 2019, Current Cardiology Reports.
[2] A. Jaffe,et al. Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. , 2019, Blood.
[3] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[4] A. Petrie,et al. A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.
[5] R. Falk,et al. ‘A new staging system for cardiac transthyretin amyloidosis’: is it already on the verge of obsolescence? , 2018, European heart journal.
[6] S. Solomon,et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[7] S. Solomon,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[8] M. Emdin,et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis , 2019, Journal of Nuclear Cardiology.
[9] C. Rapezzi,et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.
[10] S. Frusconi,et al. Different NT-proBNP circulating levels for different types of cardiac amyloidosis , 2016, Journal of cardiovascular medicine.
[11] A. Dispenzieri,et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.
[12] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[13] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[14] G. Gensini,et al. Echocardiographic and Biohumoral Characteristics in Patients With AL and TTR Amyloidosis at Diagnosis , 2015, Clinical cardiology.
[15] W. Tang,et al. A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure. , 2014, Journal of cardiac failure.
[16] S. Solomon,et al. Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.
[17] M. Maurer,et al. 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses , 2013, Circulation. Cardiovascular imaging.
[18] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Doughty,et al. Renal Dysfunction in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: Impact of the New CKD-EPI Formula , 2012 .
[20] L. Padeletti,et al. Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.
[21] S. Kimmel,et al. Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials , 2011, European journal of heart failure.
[22] S. Gottlieb,et al. Cardiorenal Syndrome: New Perspectives , 2010, Circulation.
[23] R. Falk,et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway , 2010, Proceedings of the National Academy of Sciences.
[24] M. Kroll,et al. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. , 2010, American journal of clinical pathology.
[25] Rinaldo Bellomo,et al. Cardiorenal syndrome. , 2008, Journal of the American College of Cardiology.
[26] V. Hasselblad,et al. Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.
[27] Y. Pinto,et al. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? , 2006, Journal of the American College of Cardiology.
[28] R. Fitzgerald,et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. , 2006, American journal of clinical pathology.
[29] F. Salvi,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.
[30] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Therneau,et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. , 2004, Blood.
[32] M. Skinner,et al. Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.
[33] T. Therneau,et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins , 2003, The Lancet.